{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:15:01Z","timestamp":1777515301538,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejphar.2018.09.019","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T12:21:26Z","timestamp":1537273286000},"page":"153-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["SGLT1 inhibition: Pros and cons"],"prefix":"10.1016","volume":"838","author":[{"given":"Vasilis","family":"Tsimihodimos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Filippas-Ntekouan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.09.019_bib1","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.09.019_bib2","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes","year":"2018","journal-title":"Diabetes care"},{"key":"10.1016\/j.ejphar.2018.09.019_bib3","article-title":"Cardiovascular protection in type 2 diabetes: insights from recent outcome trials","author":"Bailey","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2018.09.019_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCRESAHA.116.303584","article-title":"Regulation of signal transduction by reactive oxygen species in the cardiovascular system","volume":"116","author":"Brown","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2018.09.019_bib5","doi-asserted-by":"crossref","first-page":"263845","DOI":"10.1155\/2013\/263845","article-title":"Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db\/db mice by quantitative proteomics","volume":"2013","author":"Cai","year":"2013","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2018.09.019_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-4598-13-23","article-title":"Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis","volume":"13","author":"Cardani","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2018.09.019_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.08730816","article-title":"Association of serum triglyceride to HDL cholesterol ratio with all-cause and cardiovascular mortality in incident hemodialysis patients","volume":"12","author":"Chang","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"10.1016\/j.ejphar.2018.09.019_bib8","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/jpet.118.248575","article-title":"Potent sodium\/glucose cotransporter SGLT1\/2 dual inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in rodents","volume":"365","author":"Du","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.09.019_bib10","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.2337\/db15-0022","article-title":"Reduction in SGLT1 mRNA expression in the ventromedial hypothalamus improves the counterregulatory responses to hypoglycemia in recurrently hypoglycemic and diabetic rats","volume":"64","author":"Fan","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.09.019_bib11","unstructured":"FDA, 2015. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. \u3008https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.pdf\u3009."},{"key":"10.1016\/j.ejphar.2018.09.019_bib12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2018.09.019_bib13","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1007\/s12032-010-9696-8","article-title":"Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis","volume":"28","author":"Guo","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib15","doi-asserted-by":"crossref","first-page":"F182","DOI":"10.1152\/ajprenal.00548.2012","article-title":"Insulin directly stimulates VEGF-A production in the glomerular podocyte","volume":"305","author":"Hale","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbamem.2005.10.003","article-title":"Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells","volume":"1717","author":"Ikari","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2018.09.019_bib17","doi-asserted-by":"crossref","first-page":"43410","DOI":"10.1038\/srep43410","article-title":"Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL","volume":"7","author":"Jorissen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.09.019_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","article-title":"The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer","volume":"170","author":"Koepsell","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.09.019_bib19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00404-011-2166-5","article-title":"Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma","volume":"285","author":"Lai","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ejphar.2018.09.019_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0925-4439(98)00109-4","article-title":"Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects","volume":"1453","author":"Lam","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2018.09.019_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/MSMBR.907775","article-title":"Phlorizin Exerts direct protective effects on palmitic acid (PA)-induced endothelial dysfunction by activating the PI3K\/AKT\/eNOS signaling pathway and increasing the levels of nitric oxide (NO)","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"10.1016\/j.ejphar.2018.09.019_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2018.09.019_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ng0296-216","article-title":"Defects in Na+\/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption","volume":"12","author":"Martin","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2018.09.019_bib24","first-page":"6887","article-title":"Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts","volume":"17","author":"Meng","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2018.09.019_bib25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.09.019_bib26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/dom.13003","article-title":"Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects","volume":"19","author":"Norton","year":"2017","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.ejphar.2018.09.019_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/jpet.115.225508","article-title":"Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents","volume":"354","author":"Oguma","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.09.019_bib28","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.4049\/jimmunol.181.5.3126","article-title":"Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa","volume":"181","author":"Palazzo","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib29","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2018.09.019_bib31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2018.09.019_bib32","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/ndt\/gfh366","article-title":"Long-term outcome of renal glucosuria type 0: the original patient and his natural history","volume":"19","author":"Scholl-Burgi","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2018.09.019_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41419-018-0273-y","article-title":"Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect","volume":"9","author":"Secker","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejphar.2018.09.019_bib34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1159\/000479197","article-title":"SGLT1 deficiency turns listeria infection into a lethal disease in mice","volume":"42","author":"Sharma","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2018.09.019_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/dme.13645","article-title":"Sotagliflozin: a dual sodium-glucose co-transporter-1 and \u22122 inhibitor for the management of Type 1 and Type 2 diabetes mellitus","author":"Sims","year":"2018","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2018.09.019_bib36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","article-title":"Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes","volume":"19","author":"Solini","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2018.09.019_bib37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2018.09.019_bib38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00431-008-0681-6","article-title":"Nephrocalcinosis in glucose-galactose malabsorption: nephrocalcinosis and proximal tubular dysfunction in a young infant with a novel mutation of SGLT1","volume":"167","author":"Soylu","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ejphar.2018.09.019_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","article-title":"Glucose transporters in healthy heart and in cardiac disease","volume":"230","author":"Szablewski","year":"2017","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.14740\/jocmr3112w","article-title":"Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2\/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus","volume":"9","author":"Takebayashi","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.ejphar.2018.09.019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2018.06.003","article-title":"SGLT2 inhibitors and the kidney: effects and mechanisms","author":"Tsimihodimos","year":"2018","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.ejphar.2018.09.019_bib42","doi-asserted-by":"crossref","first-page":"41166","DOI":"10.1038\/srep41166","article-title":"Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart","volume":"7","author":"Van Steenbergen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.09.019_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2017.02.007","article-title":"Sodium influx through cerebral sodium-glucose transporter type 1 exacerbates the development of cerebral ischemic neuronal damage","volume":"799","author":"Yamazaki","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.09.019_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.diabres.2018.03.047","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: a systematic review and meta-analysis","volume":"140","author":"Zhang","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2018.09.019_bib45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918305491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918305491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:23:23Z","timestamp":1757975003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918305491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":45,"alternative-id":["S0014299918305491"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.019","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT1 inhibition: Pros and cons","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}